Cololebao

Cololebao is a Traditional Chinese Medicine (TCM) compound developed by the Beijing University of Chinese Medicine (BUCM), specifically by the research team led by Professor Wang Qingguo. It is primarily indicated for the prevention and treatment of influenza, including various strains such as H1N1 and H3N2. The formulation is based on classical TCM principles and has demonstrated antiviral activity by inhibiting viral replication and modulating the host's immune response. Specifically, research has shown that Cololebao can down-regulate the TLR7/MyD88 signaling pathway, thereby reducing the inflammatory response and lung injury associated with viral infections. It has been utilized in clinical settings in China, particularly as a hospital preparation, and continues to be a subject of study for its potential in managing viral respiratory diseases.

Brand names

Kelebao

Other names

可乐宝Kelebao Oral Liquid